Bank of Ireland Life European Ex UK

European (ex UK) (Series 2) invests in the State Street Europe Value Spotlight Fund, which in turn invests in equities from the European region only. The fund is actively managed and focuses on shares rather than bonds or cash. Its stated aim is to generate long-term capital growth.

European (ex UK) (Series 2) is exposed through the underlying fund to a diversified group of large European companies, including Astrazeneca Plc, BNP Paribas, CNH Industrial, Deutsche Boerse, Nestle, Roche, TotalEnergies SE and Volvo. These holdings suggest a broad spread across sectors such as healthcare, financials, industrials and energy. The exact mix may change over time as the underlying fund is actively managed.

European (ex UK) (Series 2) is designed for investors who want exposure to European equities and who are prepared to invest for at least 5-7 years. That longer horizon can help reduce the effect of short-term market swings, though the value can still rise or fall over time. It may suit investors seeking long-term capital growth from a regional equity fund.

European (ex UK) (Series 2) carries the usual risks of equity investing, meaning its value can fluctuate as share prices move up and down. It also has sustainability risks, which means environmental, social or governance issues could affect some of the companies it holds and therefore the fund's returns. The factsheet also notes that securities lending may be used in some funds, which can add risk while aiming to generate extra return.

European (ex UK) (Series 2) is described as investing in the European region only through the State Street Europe Value Spotlight Fund. The geographic allocation list shows some exposure labels such as U.K., Eurozone and other European equities, and also a small North American equities category in the underlying data. The fund name indicates that the UK is excluded from the main European mandate, so investors should rely on the fund documentation for the exact current allocation.